PE20141337A1 - Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida - Google Patents

Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida

Info

Publication number
PE20141337A1
PE20141337A1 PE2014000672A PE2014000672A PE20141337A1 PE 20141337 A1 PE20141337 A1 PE 20141337A1 PE 2014000672 A PE2014000672 A PE 2014000672A PE 2014000672 A PE2014000672 A PE 2014000672A PE 20141337 A1 PE20141337 A1 PE 20141337A1
Authority
PE
Peru
Prior art keywords
methyl
benzamide
imidazol
pyridinyl
trifluoro
Prior art date
Application number
PE2014000672A
Other languages
English (en)
Spanish (es)
Inventor
Upkar Bhardwaj
Mangesh Sadashiv Bordawekar
Ann Reese Comfort
Ping Li
Shoufeng Li
Alexey Makarov
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20141337A1 publication Critical patent/PE20141337A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2014000672A 2011-11-14 2012-11-12 Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida PE20141337A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161559281P 2011-11-14 2011-11-14

Publications (1)

Publication Number Publication Date
PE20141337A1 true PE20141337A1 (es) 2014-10-16

Family

ID=47324402

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000672A PE20141337A1 (es) 2011-11-14 2012-11-12 Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida

Country Status (23)

Country Link
EP (1) EP2779995A1 (enExample)
JP (1) JP6275645B2 (enExample)
KR (1) KR20140093230A (enExample)
CN (1) CN103930094A (enExample)
AR (1) AR088844A1 (enExample)
BR (1) BR112014011518A2 (enExample)
CA (1) CA2855503A1 (enExample)
CL (1) CL2014001247A1 (enExample)
CO (1) CO6960546A2 (enExample)
EA (1) EA201490960A1 (enExample)
GT (1) GT201400094A (enExample)
HK (1) HK1197025A1 (enExample)
IL (1) IL232480A0 (enExample)
IN (1) IN2014DN03416A (enExample)
MA (1) MA35636B1 (enExample)
MX (1) MX2014005874A (enExample)
PE (1) PE20141337A1 (enExample)
PH (1) PH12014501062B1 (enExample)
SG (2) SG11201401476TA (enExample)
TN (1) TN2014000177A1 (enExample)
TW (1) TWI574690B (enExample)
WO (1) WO2013074432A1 (enExample)
ZA (1) ZA201402756B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
JP7378279B2 (ja) * 2019-11-18 2023-11-13 日本化薬株式会社 ニロチニブを有効成分とする医薬錠剤及びその製造方法
JP7489849B2 (ja) * 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤
JP7776274B2 (ja) * 2021-07-19 2025-11-26 日本化薬株式会社 ニロチニブ錠剤およびその製造方法
JP7776275B2 (ja) * 2021-07-26 2025-11-26 日本化薬株式会社 ニロチニブ錠剤およびその製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
WO2012164578A1 (en) * 2011-06-02 2012-12-06 Hetero Research Foundation Compositions and methods for preparing immediate release formulations of nilotinib

Also Published As

Publication number Publication date
JP6275645B2 (ja) 2018-02-07
HK1197025A1 (en) 2015-01-02
IL232480A0 (en) 2014-06-30
TWI574690B (zh) 2017-03-21
EP2779995A1 (en) 2014-09-24
PH12014501062A1 (en) 2014-06-23
CL2014001247A1 (es) 2014-10-17
EA201490960A1 (ru) 2014-08-29
AU2012339829A1 (en) 2014-05-29
PH12014501062B1 (en) 2018-04-20
KR20140093230A (ko) 2014-07-25
GT201400094A (es) 2017-09-28
CO6960546A2 (es) 2014-05-30
AR088844A1 (es) 2014-07-10
MA35636B1 (fr) 2014-11-01
SG10201707768RA (en) 2017-10-30
JP2014533283A (ja) 2014-12-11
BR112014011518A2 (pt) 2017-05-16
NZ623844A (en) 2016-09-30
TW201325594A (zh) 2013-07-01
ZA201402756B (en) 2015-04-29
CN103930094A (zh) 2014-07-16
WO2013074432A1 (en) 2013-05-23
CA2855503A1 (en) 2013-05-23
SG11201401476TA (en) 2014-10-30
AU2012339829B2 (en) 2016-05-12
IN2014DN03416A (enExample) 2015-06-26
MX2014005874A (es) 2014-06-23
TN2014000177A1 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
AR086913A1 (es) 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
PE20120626A1 (es) Composiciones farmaceuticas que comprende nilotinib
PE20141337A1 (es) Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida
CL2016000816A1 (es) Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras.
NZ739339A (en) Apoptosis signal-regulating kinase inhibitor
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
EA201291421A1 (ru) Пероральные фармацевтические лекарственные формы, содержащие дабигатрана этексилат и его фармацевтически приемлемые соли
MY176244A (en) Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
CR20120061A (es) Tableta
BR112015021097A2 (pt) formulações de compostos orgânicos
EA201600435A1 (ru) Кристаллическая форма (s)-(2-(6-хлор-7-метил-1н-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора
MX2015012386A (es) Inhibidores de la cinasa cdk9.
AR093635A1 (es) Inhibidores de la tirosina quinasa de bruton, metodo de tratamiento, compuesto, combinacion, formulacion
HRP20171295T1 (hr) Derivat 6-okso-1,6-dihidro-piridazina za upotrebu za liječenje hepatocelularnog karcinoma (hcc)
IL182419A0 (en) Use of 4- (4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms
TH148311A (th) การปลดปล่อยที่ถูกดัดแปรของ 4-เมธิล-3-[[4-(3-ไพริดินิล)-2-ไพริมิดินิล]อะมิโน]-n-[5-(4-เมธิล-1h-อิมิดาโซล-1-อิล)-3-(ไตรฟูลออโรเมธิล)ฟีนิล] เบนซาไมด์ที่สามารถละลายได้โดยใช้กรดอินทรีย์
UY31842A (es) Inhibidor de la proteina de activacion de la lipoxigenasas-5

Legal Events

Date Code Title Description
FC Refusal